Lilly’s Verzenio Fails In KRAS Mutated Lung Cancer

Under the settlement agreement, InnoPharma can start selling a generic version of the eye drug in the United States from Feb 24, 2024 or earlier under certain circumstances. Moreover, under certain circumstances, InnoPharma will be allowed to launch an authorized generic version of Restasis on Aug 28, 2024.

Allergan is adopting different ways of protecting Restasis from generic competition. The company recently came under fire for entering into an agreement with the Saint Regis Mohawk Tribe, with lawmakers questioning the unconventional move adopted by the company to protect the blockbuster eye drug from generic competition. Restasis is Allergan’s second best-selling drug bringing in sales of almost $1.5 billion in 2016. Lawmakers pointed out that the sovereign status of Native American tribes would make any patent challenges lengthy and complex as tribes may be immune from the legal claims made by generic drug makers to challenge patents. In fact, the Tribe is filing to dismiss the ongoing inter partes review (“IPR”) of the Restasis patents based on their sovereign immunity from IPR challenges.

The deal with the Tribe has basically raised concerns that it will curb generic competition in the pharmaceutical industry and discourage generic drugmakers from making cheaper copy-cat versions of expensive drugs. Allergan has been asked by the Committee on Oversight and Government Reform to provide certain documents and information about the deal by Oct 17, 2017.

Merck Will Not File Anacetrapib:

Merck has decided that it will not seek regulatory approval for its investigational CETP inhibitor, anacetrapib. The company’s decision was based on a thorough review of the clinical profile of the drug. We note that Merck is not the first company to drop a CETP inhibitor from its plans. Companies like Lilly, Roche and Pfizer have all had high profile setbacks with their CETP inhibitors and the class was more or less written off (Read more: Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib).

CRL for AcelRx’s Dsuvia:

AcelRx Pharmaceuticals’s ACRX shares plunged 59.8% with the company getting a Complete Response Letter (“CRL”) from the FDA for Dsuvia (sufentanil sublingual tablet). The FDA said that it cannot approve the regulatory application in its current form and has asked for additional safety data. The agency has also asked the company to make certain changes to the Directions for Use to ensure the proper administration of the tablet. AcelRx has been asked to validate the same through a human factors study. AcelRx is looking to get Dsuvia approved for the reduction of moderate-to-severe acute pain and dosing errors associated with IV administration via its non-invasive single-dose applicator (“SDA”) in medically supervised settings.

Performance

Large Cap Pharmaceuticals Industry 5YR % Return

View photos

Large Cap Pharmaceuticals Industry 5YR % Return

The NYSE ARCA Pharmaceutical Index gained 0.5% this week. Among major stocks, J&J is up 2.7% while Lilly declined 1.4%. Over the last six months, Bristol-Myers Squibb BMY was up 24.9% (See the last pharma stock roundup here: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal).

View photos

What's Next in the Pharma World?

Aerie Pharmaceuticals’s AERI Rhopressa will be evaluated by an FDA advisory panel for the treatment of patients with open-angle glaucoma or ocular hypertension on October 13. The company’s shares were up on favorable briefing documents.

J&J will be reporting Q3 earnings on October 17 (Read more: J&J to Kickstart Pharma Q3 Earnings: What's in Store?).

4 Stocks to Watch after the Massive Equifax Hack

Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?

Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.

Get the new Investing Guide now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report

 

Pfizer, Inc. (PFE) : Free Stock Analysis Report

 

Eli Lilly and Company (LLY) : Free Stock Analysis Report

 

Allergan PLC. (AGN) : Free Stock Analysis Report

 

Merck & Company, Inc. (MRK) : Free Stock Analysis Report

 

AcelRx Pharmaceuticals, Inc. (ACRX) : Free Stock Analysis Report

 

Aerie Pharmaceuticals, Inc. (AERI) : Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research

Source : https://au.finance.yahoo.com/news/pharma-stock-roundup-pfizer-mulls-120612619.html

Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
Lilly’s Verzenio misses key survival goal in lung cancer
Lilly's breast cancer drug fails to help lung patients
Eli Lilly: Verzenio Phase 3 JUNIPER Study Fails To Meet Primary Endpoint
Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluat - FOX 8 WVUE New Orleans News, Weather, Sports, Social
Lilly announces positive results from phase 3 JUNIPER trial evaluating Verzenio in KRAS-mutated, advanced NSCLC
BRIEF-Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio
[LIMITED STOCK!] Related eBay Products